ATE450615T1 - Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen - Google Patents

Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen

Info

Publication number
ATE450615T1
ATE450615T1 AT06800260T AT06800260T ATE450615T1 AT E450615 T1 ATE450615 T1 AT E450615T1 AT 06800260 T AT06800260 T AT 06800260T AT 06800260 T AT06800260 T AT 06800260T AT E450615 T1 ATE450615 T1 AT E450615T1
Authority
AT
Austria
Prior art keywords
methods
fusion proteins
compositions
fgfr fusion
treating diseases
Prior art date
Application number
AT06800260T
Other languages
English (en)
Inventor
Lewis Williams
Elizabeth Bosch
Stephen Doberstein
Kevin Hestir
Diane Hollenbaugh
Ernestine Lee
Minmin Qin
Ali Sadra
Justin Wong
Ge Wu
Hongbing Zhang
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Application granted granted Critical
Publication of ATE450615T1 publication Critical patent/ATE450615T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT06800260T 2005-07-22 2006-07-24 Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen ATE450615T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70147905P 2005-07-22 2005-07-22
US72940105P 2005-10-21 2005-10-21
US75739806P 2006-01-10 2006-01-10
US80000506P 2006-05-15 2006-05-15
PCT/US2006/028597 WO2007014123A2 (en) 2005-07-22 2006-07-24 Compositions and methods of treating disease with fgfr fusion proteins

Publications (1)

Publication Number Publication Date
ATE450615T1 true ATE450615T1 (de) 2009-12-15

Family

ID=37546822

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06800260T ATE450615T1 (de) 2005-07-22 2006-07-24 Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen

Country Status (10)

Country Link
US (9) US7678890B2 (de)
EP (2) EP2083081A1 (de)
JP (4) JP4822371B1 (de)
AT (1) ATE450615T1 (de)
AU (1) AU2006272759B2 (de)
CA (1) CA2614039C (de)
DE (1) DE602006010874D1 (de)
ES (1) ES2336832T3 (de)
NZ (1) NZ565511A (de)
WO (1) WO2007014123A2 (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723290B2 (en) 2004-10-22 2010-05-25 Bioincept, Llc Compositions and methods for modulating the immune system
ATE450615T1 (de) * 2005-07-22 2009-12-15 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
WO2008133873A2 (en) * 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
JP5563818B2 (ja) * 2007-05-29 2014-07-30 北海道公立大学法人 札幌医科大学 癌治療剤及び癌の治療方法
DE102007026877A1 (de) * 2007-06-08 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Verwendung des Fibroblastenwachstumsfaktors 7 (Fgf7) und des Rezeptors Fgfr2b als Biomarker
HRP20150512T1 (hr) 2007-09-04 2015-06-19 Compugen Ltd. Polipeptidi i polinukleotidi, te njihova uporaba kao ciljnih molekula za proizvodnju lijekova i bioloških sredstava
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US20110059091A1 (en) * 2008-02-04 2011-03-10 Xiao-Jia Chang Inhibitors of oncogenic isoforms and uses thereof
NZ590050A (en) 2008-06-04 2012-08-31 Amgen Inc Fgf21 mutants and uses thereof
CN102171343B (zh) * 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
WO2010042747A2 (en) 2008-10-10 2010-04-15 Amgen Inc. Fgf21 mutants and uses thereof
EP2400985A2 (de) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Kombination eines anti-igf-1r-antikörpers oder eines igf-bindungsproteins und eines kleinmoleküligen igf-1r-kinase-inhibitors
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519281A (ja) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ，エルエルシー 間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
CN102448984A (zh) * 2009-03-27 2012-05-09 酶遗传学股份有限公司 使用包含抗体-受体组合的多特异性结合蛋白的组合物和方法
JO3469B1 (ar) * 2009-05-05 2020-07-05 Amgen Inc طافرات fgf21 واستخداماتها
EP2427207B1 (de) 2009-05-05 2017-08-16 Amgen, Inc Fgf21-mutanten und ihre verwendungen
PT2995315T (pt) 2009-05-15 2024-03-14 Hospital For Sick Children Composições e métodos para o tratamento de cancros hematológicos que visam a interação sirpa-cd47
JP2012530493A (ja) * 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド キメラポリペプチドおよびその使用
WO2011034940A1 (en) * 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
PT2498799T (pt) * 2009-11-13 2016-11-04 Five Prime Therapeutics Inc Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2
US8372952B2 (en) * 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
EP2640377B1 (de) 2010-11-15 2018-12-26 Five Prime Therapeutics, Inc. Kombinationstherapien mit extrazellulärer fgfr1-domäne
AU2015258172B2 (en) * 2010-11-15 2017-01-12 Five Prime Therapeutics, Inc. Fgfr1 extracellular domain combination therapies
AU2015249133C1 (en) * 2010-11-15 2017-08-17 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) * 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
RU2440142C1 (ru) * 2011-02-07 2012-01-20 Общество С Ограниченной Ответственностью "Онкомакс" Антитело, останавливающее или замедляющее рост опухоли (варианты), способ подавления роста опухоли, способ диагностики злокачественных образований
WO2012119072A2 (en) 2011-03-02 2012-09-07 Bioincept, Llc Compositions and methods for treatment of intracellular damage
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
BR112013029246A2 (pt) 2011-05-19 2017-02-14 Novartis Ag 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN102219859B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
PL2726092T3 (pl) 2011-06-28 2019-11-29 Inhibrx Lp Polipeptydy fuzyjne serpiny i sposoby ich stosowania
AU2012277376B2 (en) 2011-06-30 2016-11-24 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
UA118744C2 (uk) 2011-07-01 2019-03-11 ЕнДжиЕм БАЙОФАРМАСЬЮТІКАЛЗ, ІНК. Химерний пептид, композиція, що його містить, його застосування і способи лікування порушень і захворювань обміну речовин
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
EP2780033B1 (de) 2011-11-14 2019-05-08 Five Prime Therapeutics, Inc. Eine fgfr1 extrazelluläre domäne zur behandlung von krebs mit einer fgfr1 gen vervielfältigung
KR20140126357A (ko) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
WO2014035433A1 (en) * 2012-08-31 2014-03-06 Jan Nolta Genetically modified msc and therapeutic methods
CN107501413A (zh) 2012-09-27 2017-12-22 中外制药株式会社 Fgfr3融合基因和以其作为标靶的药物
WO2014071358A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
ES2949394T3 (es) * 2012-11-05 2023-09-28 Found Medicine Inc Moléculas de fusión novedosas y usos de las mismas
AU2013352363B2 (en) 2012-11-28 2018-04-12 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
EP3575326B8 (de) 2012-12-17 2022-05-25 Trillium Therapeutics ULC Behandlung von cd47+-krankheitszellen mit sirp-alpha-fc-fusionen
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
NZ630469A (en) 2012-12-27 2017-02-24 Ngm Biopharmaceuticals Inc Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
AU2013373679A1 (en) * 2013-01-16 2015-08-13 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (FGR3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック， インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
AR095464A1 (es) 2013-03-15 2015-10-21 Celgene Avilomics Res Inc Compuestos de heteroarilo y usos de los mismos
WO2014144737A1 (en) 2013-03-15 2014-09-18 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2991669A2 (de) 2013-05-01 2016-03-09 Five Prime Therapeutics, Inc. Verfahren zur behandlung von karzinomen
MX2015015426A (es) * 2013-05-23 2016-06-10 Five Prime Therapeutics Inc Metodos de tratamiento de cancer.
CA2928411A1 (en) * 2013-10-22 2015-04-30 Bioincept, Llc Pif-transfected cells and methods of use
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
CN103539862B (zh) * 2013-11-01 2015-04-01 广州联康生物科技有限公司 一种长效重组促卵泡激素及其应用
MX2016006301A (es) * 2013-11-13 2016-12-16 Zymeworks Inc Construcciones de unión a antígeno monovalente que se dirigen a egfr y/o her2, y sus usos.
HUE050279T2 (hu) 2014-01-24 2020-11-30 Ngm Biopharmaceuticals Inc Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei
EP3102705A4 (de) * 2014-02-04 2017-10-25 Mayo Foundation for Medical Education and Research Verfahren zur identifizierung von tyrosinkinaserezeptorneuanordnungen bei patienten
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
KR102569907B1 (ko) 2014-10-23 2023-08-24 엔지엠 바이오파마슈티컬스, 아이엔씨. 펩티드 변이체를 포함하는 약제학적 조성물 및 그의 사용 방법
IL308589A (en) * 2014-10-27 2024-01-01 Inhibrx Inc Serpin fusion polypeptides and methods of use thereof
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
DK3242888T3 (da) * 2015-01-07 2021-02-15 Pfizer Opløselige fgfr3-atrapper til behandling af skeletvækstforstyrrelser
WO2016191765A1 (en) * 2015-05-28 2016-12-01 Remegen, Ltd. Fgfr-fc fusion proteins and the use thereof
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
EP3341739A4 (de) 2015-08-28 2019-07-10 BioIncept LLC Mutierte peptide und verfahren zur behandlung von subjekten damit
EP3341006A4 (de) 2015-08-28 2019-03-13 BioIncept LLC Zusammensetzungen und verfahren zur behandlung von nervenschäden
CR20180306A (es) * 2015-11-02 2018-10-16 Five Prime Therapeutics Inc Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
JP7349787B2 (ja) 2015-11-23 2023-09-25 ファイヴ プライム セラピューティクス インク 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
EP3496737B1 (de) 2016-08-15 2021-11-03 The Children's Medical Center Corporation Apom-fc-fusionsproteine, komplexe davon mit sphingosin-i-phosphat (sip) und verfahren zur behandlung von vaskulären und nicht-vaskulären erkrankungen
AU2017315459B2 (en) 2016-08-26 2023-06-29 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2018095932A1 (en) 2016-11-22 2018-05-31 Merck Patent Gmbh Monoclonal antibody directed to fgfr1
ES2899616T3 (es) 2017-04-28 2022-03-14 Five Prime Therapeutics Inc Polipéptidos del dominio extracelular del CD80 para su uso en aumentar los linfocitos T de memoria central
CA3073115A1 (en) 2017-08-15 2019-02-21 Children's Medical Center Corporation Apom-fc fusion proteins and uses thereof
US20210340214A1 (en) * 2018-08-29 2021-11-04 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein dosing regimens
US12415847B2 (en) 2018-10-12 2025-09-16 Children's Medical Center Corporation ApoM-Fc fusion proteins for treating lung diseases
CA3092320C (en) * 2018-12-07 2023-09-19 Remegen Co., Ltd. Bifunctional angiogenesis inhibitor and use thereof
JP2020015733A (ja) * 2019-08-19 2020-01-30 アンセルムＩｎｓｅｒｍ 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体３（ｆｇｒ３）ポリペプチド
AU2021284297A1 (en) * 2020-06-03 2023-02-02 Dana-Farber Cancer Institute, Inc. Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same
AR123306A1 (es) 2020-08-21 2022-11-16 Genzyme Corp Anticuerpos fgfr3 y métodos de uso
US12315537B2 (en) * 2022-10-21 2025-05-27 International Business Machines Corporation Magnetic write transducer with variable write gap length

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US5486462A (en) * 1984-11-23 1996-01-23 The Regents Of The University Of California Differentiative expression modules
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
GB9001466D0 (en) * 1990-01-23 1990-03-21 Erba Carlo Spa Extracellular form of the human fibroblast growth factor receptor
US5288855A (en) 1989-01-23 1994-02-22 Farmitalia Carlo Erba Extracellular form of the human fibroblast growth factor receptor
CA2063431C (en) 1989-07-06 2002-10-29 Lewis T. Williams Receptors for fibroblast growth factors
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5750371A (en) 1990-04-27 1998-05-12 Takeda Chemical Industries Ltd Water-soluble mutein of FGF receptor, DNA and production thereof
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
WO1992000999A1 (en) 1990-07-06 1992-01-23 Rhone-Poulenc Rorer International (Holdings) Inc. Fibroblast growth factor receptors
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5229501A (en) 1991-01-11 1993-07-20 Chiron Corporation Expression and use of human fibroblast growth factor receptor
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
IL100219A0 (en) 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5474914A (en) 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
US6627616B2 (en) 1995-12-13 2003-09-30 Mirus Corporation Intravascular delivery of non-viral nucleic acid
US6323316B1 (en) 1996-06-18 2001-11-27 The United States Of America As Represented By The Secretary Of The Department Of And Human Services Fibroblast growth factor receptor activating gene 1 and related compositions and methods
SE9700384D0 (sv) 1997-02-04 1997-02-04 Biacore Ab Analytical method and apparatus
DE19802377A1 (de) 1998-01-22 1999-08-19 Max Planck Gesellschaft Verwendung von Inhibitoren für die Behandlung von RTK-Überfunktions-bedingten Störungen, insbesondere von Krebs
WO1999053017A2 (en) 1998-04-15 1999-10-21 Fred Hutchinson Cancer Research Center Methods and vector constructs for making transgenic non-human animals which ubiquitously express a heterologous gene
AU6366999A (en) 1998-10-30 2000-05-22 Takeda Chemical Industries Ltd. Betacellulin protein-containing preparations
WO2002094852A2 (en) * 2001-05-24 2002-11-28 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins
US6656728B1 (en) 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
DE60020119T2 (de) 1999-06-18 2005-10-06 Biacore Ab Verfahren und Vorrichtung zur Untersuchung von Wirksstoffskandidaten und zur Bestimmung ihrer pharmakokinetischen Parametern
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
WO2003020743A1 (en) 2001-09-05 2003-03-13 Regeneron Pharmaceuticals, Inc. Methods of expressing transgenes
US20050187150A1 (en) 2001-10-31 2005-08-25 New York University Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds
MXPA05000552A (es) * 2002-07-15 2005-04-28 Immunex Corp Metodos y medios para controlar la sialilacion de proteinas producidas por celulas de mamifero.
WO2004020605A2 (en) 2002-08-29 2004-03-11 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
WO2005066211A2 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
EP1745073A2 (de) 2004-05-14 2007-01-24 Receptor Biologix, Inc. Isoformen eines zelloberflächenrezeptors und verfahren zu deren identifizierung und anwendung
EP1773305A2 (de) 2004-05-25 2007-04-18 Yale University Corporation Verfahren zur behandlung von skeletterkrankungen infolge gestörter fgfr-funktion
WO2006081430A2 (en) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
ATE450615T1 (de) 2005-07-22 2009-12-15 Five Prime Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen
WO2007059574A1 (en) 2005-11-23 2007-05-31 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
TWI388568B (zh) 2006-02-10 2013-03-11 Genentech Inc 抗ｆｇｆ１９抗體及其使用方法
EP2018442A2 (de) 2006-05-12 2009-01-28 Genentech, Inc. Verfahren und zusammensetzungen zur diagnose und behandlung von krebs
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
US20100111873A1 (en) 2007-02-20 2010-05-06 Russell Stephen J Treating cancer with viral nucleic acid
KR20100015883A (ko) 2007-03-23 2010-02-12 더 트랜스내셔날 게노믹스 리서치 인스티튜트 자궁내막암 및 전암을 진단，분류 및 치료하는 방법
WO2008133873A2 (en) 2007-04-25 2008-11-06 Aveo Pharmaceuticals, Inc. Fgf-binding fusion proteins
CL2008003449A1 (es) 2007-11-21 2010-02-19 Imclone Llc Anticuerpo o fragmentos del mismo contra el receptor de proteína estimulante de macrófagos/ron; composición farmacéutica que lo comprende; uso para inhibir angiogénesis, crecimiento tumoral, proliferación, migración e invasión de células tumorales, activación de ron o fosforilación de mapk y/o akt; y uso para tratar cáncer.
CN102171343B (zh) 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
PT2498799T (pt) 2009-11-13 2016-11-04 Five Prime Therapeutics Inc Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2
US8685931B2 (en) 2009-12-17 2014-04-01 Five Prime Therapeutics, Inc. Hair growth methods using FGFR3 extracellular domains
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
IT1404531B1 (it) 2011-02-24 2013-11-22 Sisvel Technology Srl Procedimento e sistema di localizzazione indoor per terminali mobili in una rete di telecomunicazione mobile cellulare e relativo terminale mobile.
MA34966B1 (fr) 2011-03-17 2014-03-01 Novartis Ag Fgfr et ses ligands utilisés comme biomarqueurs du cancer du sein chez des sujets rh positifs
US20140294820A1 (en) 2011-06-24 2014-10-02 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
EP2780033B1 (de) 2011-11-14 2019-05-08 Five Prime Therapeutics, Inc. Eine fgfr1 extrazelluläre domäne zur behandlung von krebs mit einer fgfr1 gen vervielfältigung
EP2991669A2 (de) 2013-05-01 2016-03-09 Five Prime Therapeutics, Inc. Verfahren zur behandlung von karzinomen

Also Published As

Publication number Publication date
US9192683B2 (en) 2015-11-24
US8173134B2 (en) 2012-05-08
JP5889505B2 (ja) 2016-03-22
JP2013017484A (ja) 2013-01-31
US9173957B2 (en) 2015-11-03
WO2007014123A2 (en) 2007-02-01
JP6110091B2 (ja) 2017-04-05
US8501191B2 (en) 2013-08-06
US20080171689A1 (en) 2008-07-17
US7678890B2 (en) 2010-03-16
US20140140995A1 (en) 2014-05-22
HK1118857A1 (en) 2009-02-20
US20120301921A1 (en) 2012-11-29
EP2083081A1 (de) 2009-07-29
WO2007014123A3 (en) 2007-11-15
US20130065276A1 (en) 2013-03-14
US20110281302A1 (en) 2011-11-17
US20100158911A1 (en) 2010-06-24
ES2336832T3 (es) 2010-04-16
NZ565511A (en) 2011-03-31
AU2006272759B2 (en) 2012-01-12
EP1910542A2 (de) 2008-04-16
JP2014240413A (ja) 2014-12-25
US7982014B2 (en) 2011-07-19
EP1910542B1 (de) 2009-12-02
JP2014519308A (ja) 2014-08-14
US8580936B2 (en) 2013-11-12
US20130324701A1 (en) 2013-12-05
DE602006010874D1 (de) 2010-01-14
US20170349643A1 (en) 2017-12-07
CA2614039C (en) 2015-10-13
JP4822371B1 (ja) 2011-11-24
AU2006272759A1 (en) 2007-02-01
CA2614039A1 (en) 2007-02-01
US20160096876A1 (en) 2016-04-07
JP2008222711A (ja) 2008-09-25

Similar Documents

Publication Publication Date Title
ATE450615T1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen
DE602005019167D1 (de) Angiopoietin-like 4 protein hemmer kombinationen und deren verwendung
Silver et al. Contributions of chondroitin sulfate proteoglycans to neurodevelopment, injury, and cancer
ATE520403T1 (de) N-ä3-fluoro-4-(ä6-(methyloxy)-7-ä(3-morpholin-4 ylpropyl)oxyüquinolin-4-ylüoxy)phenylü-n'-(4- fluorophenyl)cyclopropane-1,1-dicarboxamid zur behandlung von krebs
ATE511857T1 (de) Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs
Li et al. EGFR signaling-dependent inhibition of glioblastoma growth by ginsenoside Rh2
MX2010009743A (es) Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
CY1119774T1 (el) Χρηση πρωτεϊνων εξωκυτταρικου πεδιου του fgfr1 για την αγωγη καρκινων χαρακτηριζομενων απο εξαρτωμενες απο προσδεμα ενεργοποιητικες μεταλλαξεις στο fgfr2
FI3478723T3 (fi) Pd-l1-spesifisiä vasta-aineita ja niiden käyttömenetelmiä
EA201490974A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С ДЕЛЕЦИОННЫМ МУТАНТОМ vIII ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА
MX2009003704A (es) Inhibidores de cinasa utiles para el tratamiento de enfermedades mileoproliferativas y otras enfermedades proliferativas.
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
EA200970729A1 (ru) Варианты, происходящие из actriib, и их применение
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
EA200701250A1 (ru) Иммуноконъюгаты против интегрина, способы и варианты применения
CN102250246A (zh) 抗VEGF/PDGFRβ双特异性抗体及其应用
DK2305255T3 (da) Arylurinstofforbindelser i kombination med andre cytostatiske eller cytotoksiske midler til behandling af humane cancere
MX2016007748A (es) Composiciones y métodos para tratar, prevenir y diagnosticar cáncer y otros trastornos proliferativos.
Cea et al. Antiangiogenic therapy for glioma
BRPI0410875A (pt) método de inibição do crescimento de tumor com anticorpos de fator antitecido
WO2010108665A1 (en) Promotion of neuronal integration in neural stem cell grafts
Aglianò et al. Characterization of lymphatic vessels in human peripheral neuropathies
BR112023024775A2 (pt) Uso de uma composição terapêutica, e, método de estratificação de pacientes
Yang et al. Platelet Glycoprotein VI Inhabitable MXene-Incorporated Fibrous Scaffolds for Preventing Tumor Progression and Metastasis
EA202091688A1 (ru) Конъюгаты антител к тканевому фактору с лекарственными средствами и их применение при лечении рака

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties